Controle precoce do ritmo em pacientes com fibrilação atrial e câncer: uma análise de subgrupo do estudo EAST-AFNET 4

Resumo original em inglês

O que aconteceu

Early rhythm-control improves cardiovascular outcomes in patients with atrial fibrillation (AF). Its effectiveness in patients with cancer is unclear. This study evaluated the effects of cancer history on early rhythm control in the EAST-AFNET 4 trial.

ClinicalTrials.gov Identifier: NCT01288352.

O que encontraram

This secondary analysis of EAST-AFNET 4 compared patients with and without a history of cancer, including active cancer and cancer in remission. Outcomes included the primary outcome, a composite of cardiovascular death, stroke, or hospitalization for worsening heart failure or acute coronary syndrome; the safety outcome, a composite of death, stroke, and serious adverse events related to rhythm control; and rhythm at 24 months. Cancer history was available in 2779 of 2789 patients (99.6%). Cancer history was present in 216 of 2779 (7.8%; 19 with active cancer; mean age, 73 years; 95 [44%] women; mean CHA2DS2-VASc score, 3.5). During a follow-up of 8.6 years, early rhythm control reduced the primary outcome in patients with and without a history of cancer (Pinteraction = 0.23) with high rates of sinus rhythm at 24 months (cancer: 84.9%, without cancer: 81.8%; Pinteraction = 0.60). In patients with a cancer history, there was a signal for more safety outcomes with early rhythm control [early rhythm control 36/116 (31%) patients with event, 22 deaths; usual care 20/100 (20%) patients with event, 18 deaths; Pinteraction = 0.055].

Por que isso importa

Early rhythm control therapy appears effective in patients with AF and a history of cancer but may be less safe than in patients without cancer, in this hypothesis-generating analysis. This could be a play of chance but warrants further research into the safety and efficacy of rhythm control therapy in patients with a cancer history.

Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.